Status:
RECRUITING
Pacemaker-related Tricuspid Regurgitation Progression and Long-term Outcomes
Lead Sponsor:
Haiyan Wang
Conditions:
Tricuspid Regurgitation
Pacemaker
Eligibility:
All Genders
18+ years
Brief Summary
Tricuspid regurgitation (TR) is a common complication following cardiac implantable electronic device (CIED) implantation, with severe TR being associated with increased rates of heart failure hospita...
Detailed Description
This retrospective study analyzed patients undergoing pacemaker implantation from January 2015 to March 2025, stratified by pacing modality (right ventricular/conduction system/biventricular pacing) a...
Eligibility Criteria
Inclusion
- Adult patients
- Patients with an implantable electronic heart device (CIEDs)
- The patient underwent pacemaker implantation at Qianfoshan Hospital between 2015 and 2025
Exclusion
- Patients with severe tricuspid regurgitation or those who have undergone tricuspid valve surgery or interventional treatment prior to pacemaker implantation
- Patients with severe valvular heart disease, congenital heart disease, or arrhythmias
- Patients with single-chamber pacemakers or poor images
Key Trial Info
Start Date :
April 1 2025
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2026
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT06922526
Start Date
April 1 2025
End Date
May 1 2026
Last Update
April 30 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The First Affiliated Hospital of Shandong First Medical University
Jinan, China, 250000